Stem cells are important because they can do something no other cell in the body can: make copies of themselves indefinitely while also transforming into specialized cell types like nerve cells, heart muscle, or insulin-producing cells. This dual ability makes them essential to how the body develops, heals, and maintains itself throughout life. It also makes them one of the most powerful tools in modern medicine, with applications ranging from treating blood cancers today to potentially curing Parkinson’s disease and Type 1 diabetes in the near future.
What Makes Stem Cells Unique
Two properties set stem cells apart from every other cell type. The first is self-renewal: a stem cell can divide to produce at least one daughter cell that remains a stem cell, keeping the supply going. This happens through two mechanisms. In symmetric division, one stem cell splits into two identical stem cells. In asymmetric division, one daughter stays a stem cell while the other begins specializing. This balance between copying and specializing is what keeps tissues like skin, blood, and the gut lining constantly replenished over a lifetime.
The second property is differentiation, the ability to mature into specific cell types. Not all stem cells have equal range. A fertilized egg produces about 30 totipotent cells capable of becoming any cell type in the body, including the placenta. Embryonic stem cells are pluripotent, meaning they can become nearly any cell type but not placental tissue. Adult stem cells found in bone marrow, fat, and other tissues are multipotent, limited to producing a narrower set of related cell types. Some adult stem cells are unipotent, able to generate only one cell type but still capable of self-renewal.
Treating Blood Diseases Today
The most established use of stem cells is in treating blood cancers and disorders. The FDA has approved roughly a dozen stem cell and cord blood products for clinical use, nearly all of them hematopoietic (blood-forming) stem cell products derived from umbilical cord blood. These include products like Allocord, Hemacord, and Ducord, among others. In a typical transplant, a patient’s diseased bone marrow is destroyed with chemotherapy or radiation, then replaced with healthy stem cells that rebuild the blood and immune system from scratch. This approach has been standard care for leukemia, lymphoma, and certain genetic blood disorders for decades, and it remains the clearest example of stem cells saving lives in routine clinical practice.
Repairing the Heart
Heart failure remains one of the leading causes of death worldwide, partly because heart muscle doesn’t regenerate well on its own after a heart attack. Stem cell therapies aim to change that. In the C-CURE trial, researchers took stem cells from patients’ bone marrow, treated them with a cocktail that pushed the cells toward becoming heart cells, then injected them back into the heart. Patients experienced a 7% increase in the heart’s pumping efficiency, a 24.8 milliliter reduction in the volume of blood left in the heart after each beat, and the ability to walk 62 meters farther in a six-minute walking test. Those numbers may sound modest, but for someone with heart failure, a 7% improvement in pumping function can mean the difference between being housebound and walking to the grocery store.
Restoring Vision
Chemical burns and certain diseases can destroy the limbal stem cells that maintain the clear surface of the eye, leading to pain, scarring, and blindness. Transplanting healthy limbal stem cells can restore a stable, clear corneal surface. A large meta-analysis found that when patients received their own limbal stem cells from their uninjured eye (autologous transplant), the failure rate was just 14.3%. When donor cells were used instead, the failure rate climbed to around 42%, largely because of immune rejection. For people who have lost vision in one eye from a chemical burn but have a healthy other eye, this procedure offers a roughly 85% chance of restoring a functional ocular surface.
Progress Toward Curing Type 1 Diabetes
In Type 1 diabetes, the immune system destroys the insulin-producing beta cells in the pancreas. Replacing those cells has been a goal for decades, and stem cell technology is now making it possible. Vertex Pharmaceuticals developed a method to grow mature beta cells from stem cells and began transplanting them into patients’ livers in 2021. By mid-2024, 12 patients had received the cells. Of those, 11 showed dramatically reduced insulin needs or complete insulin independence, and all maintained healthy blood sugar levels more than 70% of the time on continuous glucose monitors.
Two additional trials in China took a different approach, using patients’ own skin cells to create stem cells that were then converted into insulin-producing cells. Because these cells are genetically identical to the patient, they theoretically don’t trigger immune rejection, eliminating the need for lifelong immunosuppression drugs. Both trials reported insulin independence in their initial patients. If these results hold up in larger studies, stem cell-derived beta cells could transform Type 1 diabetes from a lifelong condition requiring constant management into a one-time procedure.
Neurological Disease and Brain Repair
Parkinson’s disease is caused by the gradual death of a specific population of brain cells that produce dopamine, a chemical messenger essential for smooth, controlled movement. Replacing those cells has long seemed like a natural fit for stem cell therapy, and clinical trials are now underway. A Phase 1 trial is testing dopamine-producing cells grown from patients’ own skin cells, reprogrammed into stem cells, then matured into the specific brain cell type that Parkinson’s destroys. Patients receive either 4 million or 8 million of these cells injected directly into the brain. The trial is currently enrolling patients, so results aren’t yet available, but the approach represents a fundamental shift: rather than managing symptoms with medication, the goal is to replace the cells that are actually lost.
Growing Miniature Organs in the Lab
One of the most striking recent developments is the ability to grow organoids, tiny three-dimensional structures that mimic real organs. Researchers have coaxed stem cells into forming miniature versions of the brain, retina, pituitary gland, kidney, and intestine. These aren’t functional organs ready for transplant. They’re simplified models, often just millimeters across, but they recapitulate key features of how organs develop and function.
Brain organoids, for example, replicate the process by which neural stem cells near the brain’s inner cavities divide and produce waves of different neuron types that migrate outward to form layered structures resembling the cerebral cortex. This allows researchers to study neurological diseases in human tissue rather than relying solely on animal models. Organoids derived from individual patients could eventually predict how a specific person will respond to a drug, opening the door to truly personalized treatment decisions.
Making Drug Development Safer
Before a new drug reaches patients, it has to be tested for toxicity, and heart toxicity is one of the most common reasons drugs fail or get pulled from the market. Stem cells are changing how that testing works. Researchers can now take skin or blood cells from people with diverse genetic backgrounds and disease histories, reprogram them into stem cells, and then mature those stem cells into beating heart cells in a dish. These lab-grown heart cells respond to drugs much the way a patient’s actual heart would, revealing dangerous side effects before a drug ever enters a human body.
This technology is particularly valuable because drug toxicity isn’t one-size-fits-all. A medication that’s safe for most people can cause fatal heart rhythm problems in someone with a specific genetic variant. By testing drugs against heart cells derived from genetically diverse populations, researchers can identify which patients are at risk and potentially flag dangerous drugs earlier in development, reducing both the cost of bringing drugs to market and the risk to patients once they get there.